vinorelbine glenmark 20 mg
glenmark pharmaceuticals s.r.o., Česká republika - vinorelbín - 44 - cytostatica
ondansetron kalceks 2 mg/ml injekčný/infúzny roztok
as kalceks, lotyšsko - ondansetrón - 20 - antiemetica, antivertiginosa
ondansetron kabi 0,16 mg/ml
fresenius kabi deutschland gmbh, nemecko - ondansetrón - 20 - antiemetica, antivertiginosa
ondansetron kabi 0,08 mg/ml
fresenius kabi deutschland gmbh, nemecko - ondansetrón - 20 - antiemetica, antivertiginosa
vinorelbine medac 80 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
vinorelbine medac 30 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
vinorelbine medac 20 mg mäkké kapsuly
medac gesellschaft für klinische spezialpräparate m.b.h., nemecko - vinorelbín - 44 - cytostatica
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastické činidlá - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.